Bupropion???An Antidepressant Without Sexual Pathophysiological Action

Gardner, Elmer A.; Johnston, J. Andrew

doi:10.1097/00004714-198502000-00005

Cited by 67 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The antidepressant properties of bupropion have been demonstrated in controlled and open-label studies of psychiatric patient samples (22)(23)(24)(25), and it has gained favor for having efficacy comparable to that of other antidepressants yet with fewer side effects (22,26,27). Bupropion does not interfere with sexual functioning and has been associated with significantly greater weight loss compared with placebo in randomized, double-blind, placebo-controlled studies of overweight and obese individuals with (28) and without (29) depression.…”

mentioning

confidence: 99%

Factors Influencing Glycemic Control in Type 2 Diabetes During Acute- and Maintenance-Phase Treatment of Major Depressive Disorder With Bupropion

et al. 2007

View full text Add to dashboard Cite

OBJECTIVE -Depression management in both short-and longer-term treatment studies has been associated with improvement in glycemic control. We used bupropion hydrochloride (Wellbutrin XL) to determine whether this improvement could be attributed to changes in anthropometrics or diabetes self-care.RESEARCH DESIGN AND METHODS -Ninety-three patients with type 2 diabetes and major depressive disorder (MDD) received bupropion hydrochloride in a two-phase, openlabel treatment trial. Those who completed the acute phase (10 weeks; n ϭ 75) and whose depression remitted (n ϭ 63) continued bupropion at the remission dose and were followed in the maintenance phase (24 weeks) until attrition (n ϭ 8) or relapse of MDD (n ϭ 0). Self-report scales were used to measure depression symptom severity and diabetes self-care behaviors. Body composition and glycemic control were determined using dual-energy X-ray absorptiometry and serial determinations of A1C.RESULTS -BMI, total fat mass, and A1C decreased and composite diabetes self-care improved over the acute phase (Ϫ0.5 kg/m 2 , Ϫ0.7 kg, Ϫ0.5%, and ϩ0.4, respectively, P Ͻ 0.01 for each), effects that persisted through the maintenance phase for BMI, A1C, and self-care (P Յ 0.01 for each). Reductions in BMI (B ϭ 0.30, P ϭ 0.01) and depression severity (B ϭ 0.04, P ϭ 0.046) independently predicted lower A1C after acute-phase treatment, whereas only reduction in depression severity (B ϭ 0.08, P ϭ 0.001) predicted A1C over the maintenance interval.CONCLUSIONS -In the short term, improvement in glycemic control during bupropion treatment is predicted independently by improvements in mood and body composition. Longerterm improvements in glycemic control are predicted primarily by sustained improvement in mood via mechanisms independent of anthropometric and self-care modifications. Diabetes Care 30:459 -466, 2007

show abstract

mentioning

confidence: 99%

Factors Influencing Glycemic Control in Type 2 Diabetes During Acute- and Maintenance-Phase Treatment of Major Depressive Disorder With Bupropion

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Previous treatments for SSRI-induced sexual dysfunction have included adjunctive treatment with yohimbine (2), amantadine (3), cyproheptadine (4), bupropion (5), nefazodone (6), buspirone (7), granisetron (8), and sildenafil (9). Other strategies have included drug holidays (10), dose decreases (11), waiting for tolerance to develop (12), and switching to another antidepressant or another class of drug that is known to cause lower rates of sexual dysfunction (13).…”

mentioning

confidence: 99%

Sustained-Release Bupropion for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Masand¹,

Ashton²,

Gupta³

et al. 2001

AJP

View full text Add to dashboard Cite

show abstract

“…Another non-hormonal treatment is bupropion, which is an antidepressant that, unlike other antidepressants that negatively infl uence sexual function, seems to increase libido and is generally well tolerated. Side effects of bupropion to be aware of include diffi culties with concentration, insomnia and tremors [67]. Other alternatives such as melanocortins and pilocarpine have also been shown to improve sexual dysfunction [68] and vaginal dryness [69], respectively.…”

Section: What To Do About Gynaecologic Alterations Such As Vaginal Drmentioning

confidence: 99%

Supportive care for patients with early breast cancer

et al. 2010

View full text Add to dashboard Cite

Breast cancer treatment currently requires the joint efforts of a multidisciplinary team to effectively combine chemotherapy, hormone therapy, biological agents, surgery and radiation therapy when needed. To develop such a treatment plan, it is important to know the benefits as well as the potential toxic effects of each therapy. Thus, many patients with early breast cancer complain of collateral adverse events such as fatigue, nausea, vomiting, loss of libido, hot flashes, night sweats or neuropathy due to the complex therapies they are receiving. To date, the treatment of such symptoms is an important issue that greatly affects the quality of life of these patients. In this review, we report the content of a multi-expert meeting where the incidence of and medical approach to some of the most common adverse events encountered during the treatment of patients with early breast cancer were analysed.

show abstract

Bupropion???An Antidepressant Without Sexual Pathophysiological Action

Cited by 67 publications

References 0 publications

Factors Influencing Glycemic Control in Type 2 Diabetes During Acute- and Maintenance-Phase Treatment of Major Depressive Disorder With Bupropion

Factors Influencing Glycemic Control in Type 2 Diabetes During Acute- and Maintenance-Phase Treatment of Major Depressive Disorder With Bupropion

Sustained-Release Bupropion for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Supportive care for patients with early breast cancer

Contact Info

Product

Resources

About